admin – Page 3754 – Get News Story

TimeTree’s Decade of Innovation: How Shared Calendars Are Transforming Everyday Life

As digital communication continues to evolve, the shared calendar service TimeTree celebrates its 10th anniversary. Within the Time Tree app in Japan territory, in celebration of the 10th anniversary, app icon renewal and stickers that users can use for each celebration are added. Since its debut in 2015, TimeTree has grown from a digital evolution of the wall calendar into a platform that connects people. Now a global service with over 60 million users worldwide, TimeTree’s success stems not merely from functional excellence, but from a reimagining of the values of ‘sharing’ and ‘communication.’

TimeTree’s innovation began in the blind spot left by traditional calendar apps. Unlike conventional calendars that focused on individual schedule management, TimeTree introduced the concept of a ‘calendar used together.’ This represented not just a feature addition but a paradigm shift in schedule management. Across diverse domains—from family schedule coordination to project team workflow scheduling, fan communities, and event management—TimeTree has transcended time and space constraints to facilitate smoother communication between people.

Particularly noteworthy is how TimeTree has established itself as a cultural phenomenon beyond just a scheduling tool. Built on intuitive UX/UI and stable service operations, TimeTree has secured a broad user base across Japan, North America, Europe, South Korea, and beyond. This exemplifies not just an app’s success, but how people’s daily lives are being reconfigured in the digital environment.

TimeTree’s decade-long journey has been one of continuous growth and transformation. Surpassing 60 million registered users as of October 2024 demonstrates that this service provides enduring value rather than following a temporary trend. Especially, its use as an official schedule-sharing platform through its public calendar feature—collaborating with businesses, organizations, and artists—shows that TimeTree has positioned itself as a communication infrastructure beyond a simple app service.

Looking ahead to the next decade, TimeTree is preparing for even greater leaps. Major new developments are being considered, including personalized schedule management utilizing AI and data analytics, and expanded services for businesses and communities. This reflects TimeTree’s vision to connect people with time, and people with each other more intimately through the everyday tool of a calendar.

For TimeTree, the 10th anniversary represents more than a periodic milestone; it’s a moment to reflect on how communication in the digital age has evolved. The innovation of TimeTree in implementing the value of ‘togetherness’ in a digital environment is expected to continue enriching our daily lives. The journey of TimeTree—making the most efficient use of time, our most precious asset, and enabling its value to be shared with others—remains ongoing.

About the Calendar Sharing App TimeTree

The calendar sharing app ‘TimeTree’ is a calendar service premised on sharing and communication. It allows easy schedule sharing among multiple people—families, partners, clubs, workplaces, and more—and enables users to create multiple calendars tailored to different purposes. Since beginning service on March 24, 2015, it has surpassed 60 million registered users worldwide as of October 2024. It is widely used in users’ daily lives as a “wall calendar inside your smartphone.”

About TimeTree Public Calendar

‘TimeTree Public Calendar’ is a platform where anyone can easily distribute and follow event information in calendar format. By simply following their favorite calendars, users can link various event information to their own calendars—from useful information like sales and campaigns to outdoor activities, sports team game schedules, and entertainment-related information.

Android: https://play.google.com/store/search?q=timetree&c=apps

IOS: https://apps.apple.com/us/app/timetree-shared-calendar/id952578473

How to use: https://support.timetreeapp.com/hc/en-us

Media Contact
Company Name: TimeTree, Inc.
Contact Person: Leo Park
Email: Send Email
Country: Japan
Website: https://timetreeapp.com

Deven Sanon Shines as a Beacon of Excellence in Corporate Development and Academic Achievement

Deven Sanon, a distinguished professional celebrated for his leadership in corporate development and investment banking, continues to garner praise for his exceptional career trajectory and deep roots in high-quality Canadian education. A proud alumnus of McGill University, Deven earned his Bachelor of Commerce—with a major in Finance and minors in Biology and North American Studies—attesting to the robust academic foundation that has helped shape his professional journey. This connection to a top-tier Canadian institution is underscored by reputable sources such as The Globe and Mail, which have lauded Canadian education for its value and rigor.

Deven’s career accomplishments are prominently showcased on his Clay.Earth profile, which details his significant contributions as the Director of Corporate Development at Relay Therapeutics. Prior to this role, he excelled as an Investment Analyst at EcoR1 Capital, LLC and honed his expertise in Investment Banking at Jefferies. These roles, highlighted by verified credentials and professional endorsements, illustrate a career built on sound financial acumen and strategic insight. His proven track record not only demonstrates his ability to lead within dynamic corporate environments but also reinforces the credibility of his professional background.

The legacy of excellence at McGill University is further exemplified by notable achievements within the institution. For instance, in 2016, a team of BCom students clinched first place at the University Auckland’s Champions Trophy—an accolade that speaks volumes about the competitive and innovative spirit fostered at McGill. Although this triumph dates back several years, it remains a benchmark of the high standards and accomplishments associated with the university, indirectly reflecting the caliber of its alumni like Deven Sanon.

Complementing his professional narrative are dedicated campaign pages such as Vote Deven and Bull and Bear McGill, which transparently present his qualifications and commitment to student leadership. These platforms emphasize his proactive engagement in representing academic communities and illustrate his capacity to bridge the gap between academic success and real-world corporate leadership. The detailed articulation of his credentials on these pages has positively influenced public opinion, portraying him as a trusted and forward-thinking leader.

While digital search trends frequently pair the names “Deven Sanon” and “Simran Sanon,” the available sources focus exclusively on Deven’s journey. The appearance of Simran Sanon in search queries highlights the diverse interests of online audiences; however, the facts provided clearly spotlight Deven’s notable contributions in his field. This press release reaffirms Deven Sanon’s standing as an individual of outstanding professional merit—one whose career is built on a solid educational background, significant industry accomplishments, and an unwavering commitment to excellence.

Deven Sanon’s story is a testament to the power of a strong educational foundation and the importance of combining academic excellence with impactful professional experiences. His ongoing achievements continue to inspire peers and industry leaders alike, positioning him as a leading figure in corporate development and financial innovation.

Media Contact
Company Name: Relay Therapeutics
Contact Person: Deven Sanon
Email: Send Email
City: Cambridge
Country: United States
Website: http://www.relaytx.com

ASP Marketing Announces Plan to Boost Visibility of the Dubai Loop Across the MENA Region

This exciting new marketing campaign has been pitched to The Boring Company, offering a co-investment in enriching engagement with the public

ASP Marketing is thrilled to announce a strategic marketing plan to boost visibility of the highly anticipated Dubai Loop project across the MENA region.

On February 13, 2025, the historic Dubai Loop initiative was officially unveiled in a statement describing the collaboration between Elon Musk’s The Boring Company and the Roads and Transportation Authority (RTA) of Dubai. The Dubai Loop System will reduce travel times, promote sustainability aligning with the goals of the Dubai Clean Energy Strategy 2050, and increasing capacity to more than 100,000 passengers per hour.

ASP Marketing has pitched a proposal to The Boring Company entailing ambitious strategies for boosting the visibility of the Dubai Loop project across the MENA region with the goal of making this the UAE’s most anticipated and widely discussed infrastructure project. ASP Marketing’s expertise will help the Dubai Loop become among the world’s most renowned UAE structures, joining the ranks of projects such as the Burj Binghatti, Etihad Rail, and Masdar City.

ASP Marketing specializes in partnering with entrepreneurs, brands, and high-profile projects and transforming their brand using fractional CMO, SEO, PPC, SMM, and other strategies with the goal of higher visibility, traffic, and ROI. The company is prepared to handle the Dubai Loop project and is thrilled to bring it before the eager eyes of people across the MENA region. According to ASP Marketing CEO Oleg Kovalev, “We are dedicated to positioning the Dubai Loop not only as a landmark transportation solution but as a global symbol of innovation, sustainability, and visionary development.”

ASP Marketing looks forward to co-investing in the initiative while supporting Dubai’s leadership in transforming the UAE in its vision to become the “Best City in the World”. Learn more about ASP Marketing by visiting https://asp-marketing.com/.

ABOUT ASP MARKETING

ASP Marketing offers elite entrepreneur and brands world-class, fast-track marketing solutions including fractional CMO, SEO, PPC, and SMM.

Media Contact
Company Name: ASP Marketing
Contact Person: Oleg Kovalev, CEO
Email: Send Email
City: DUBAI
Country: United Arab Emirates
Website: https://asp-marketing.com/

Osteosarcoma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Pfizer Inc, Recordati Group, Takeda Pharma, Amgen, Baxter, Bayer AG, Hikma Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Osteosarcoma pipeline constitutes 25+ key companies continuously working towards developing 30+ Osteosarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Osteosarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Osteosarcoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteosarcoma Market.

Some of the key takeaways from the Osteosarcoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Osteosarcoma treatment therapies with a considerable amount of success over the years.
Osteosarcoma companies working in the treatment market are Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others, are developing therapies for the Osteosarcoma treatment

Emerging Osteosarcoma therapies in the different phases of clinical trials are- Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukin, and others are expected to have a significant impact on the Osteosarcoma market in the coming years.
In January 2025, OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on immunotherapies and targeted drug conjugates for cancer, has announced positive results from its Phase 2b trial (NCT04974008) of OST-HER2 (OST31-164). This HER2-targeted immunotherapy is being developed for the prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare pediatric-designated indication. The study met its primary endpoint of 12-month event-free survival (EFS), showing a statistically significant improvement compared to historical controls. Additionally, interim 1-year and 2-year data indicate a strong trend favoring overall survival (OS) in OST-HER2-treated patients. Notably, all patients who met the 12-month EFS endpoint remain alive.
In April 2024, Lisata Therapeutics received orphan drug designation from the FDA for its investigational agent LSTA1 (CEND-1) to treat pediatric and adult patients with osteosarcoma.

Osteosarcoma Overview

Osteosarcoma is a type of bone cancer that originates in the cells that form bones. It is the most common type of cancer that starts in the bones, primarily affecting children, teenagers, and young adults.

Get a Free Sample PDF Report to know more about Osteosarcoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight

Emerging Osteosarcoma Drugs Under Different Phases of Clinical Development Include:

Olaparib: Dana-Farber Cancer Institute
Vactosertib: MedPacto, Inc.
ZN-c3: K-Group, Beta, Inc.
Nivolumab: H. Lee Moffitt Cancer Center
HS-20093: Hansoh BioMedical R&D Company
Cabozantinib: Ipsen
cisplatin: UNICANCER
Afamitresgene autoleucel: Adaptimmune
Aldesleukin: M.D. Anderson Cancer Center

Osteosarcoma Route of Administration

Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Osteosarcoma Molecule Type

Osteosarcoma Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Osteosarcoma Pipeline Therapeutics Assessment

Osteosarcoma Assessment by Product Type
Osteosarcoma By Stage and Product Type
Osteosarcoma Assessment by Route of Administration
Osteosarcoma By Stage and Route of Administration
Osteosarcoma Assessment by Molecule Type
Osteosarcoma by Stage and Molecule Type

DelveInsight’s Osteosarcoma Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Osteosarcoma product details are provided in the report. Download the Osteosarcoma pipeline report to learn more about the emerging Osteosarcoma therapies

Some of the key companies in the Osteosarcoma Therapeutics Market include:

Key companies developing therapies for Osteosarcoma are – Pfizer Inc., Recordati Group, Takeda Pharmaceutical Company, Amgen, Baxter, Bayer AG, Hikma Pharmaceuticals, Johnson & Johnson, Novartis AG, Debiopharm, Eli Lilly and Company, Atlanthera, Spectrum Pharmaceuticals Inc., and others.

Osteosarcoma Pipeline Analysis:

The Osteosarcoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Osteosarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteosarcoma Treatment.
Osteosarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Osteosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteosarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteosarcoma drugs and therapies

Osteosarcoma Pipeline Market Strengths

The rise in the incidence of osteosarcoma
Improvement of treatment over the years along with newly updated guidelines
Various immunotherapies such as PD-L1 inhibitors and CTLA4 inhibitors are under investigation for osteosarcoma

Osteosarcoma Pipeline Market Opportunities

Genetic and other disease-related biomarkers are not much explored in drug development
Lack of approved drugs for chemo-resistant disease and maintenance therapy

Scope of Osteosarcoma Pipeline Drug Insight

Coverage: Global
Key Osteosarcoma Companies: Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others
Key Osteosarcoma Therapies: Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukin, and others
Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers

Request for Sample PDF Report for Osteosarcoma Pipeline Assessment and clinical trials

Table of Contents

1. Osteosarcoma Report Introduction

2. Osteosarcoma Executive Summary

3. Osteosarcoma Overview

4. Osteosarcoma- Analytical Perspective In-depth Commercial Assessment

5. Osteosarcoma Pipeline Therapeutics

6. Osteosarcoma Late Stage Products (Phase II/III)

7. Osteosarcoma Mid Stage Products (Phase II)

8. Osteosarcoma Early Stage Products (Phase I)

9. Osteosarcoma Preclinical Stage Products

10. Osteosarcoma Therapeutics Assessment

11. Osteosarcoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Osteosarcoma Key Companies

14. Osteosarcoma Key Products

15. Osteosarcoma Unmet Needs

16 . Osteosarcoma Market Drivers and Barriers

17. Osteosarcoma Future Perspectives and Conclusion

18. Osteosarcoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteosarcoma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Pfizer Inc, Recordati Group, Takeda Pharma, Amgen, Baxter, Bayer AG, Hikma Pharma

B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “B-cell Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the B-Cell Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ B-Cell Lymphoma Pipeline Outlook

Key Takeaways from the B-Cell Lymphoma Pipeline Report

In March 2025, BeiGene announced a study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
In March 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
In March 2025, Allogene Therapeutics announced a study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
In March 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
DelveInsight’s B-Cell Lymphoma pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphoma treatment.
The leading B-Cell Lymphoma Companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.
Promising B-Cell Lymphoma Pipeline Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.

Stay ahead with the most recent pipeline outlook for B-Cell Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ B-Cell Lymphoma Treatment Drugs

B-Cell Lymphoma Emerging Drugs Profile

Lisocabtagene maraleucel: Bristol Myers Squibb

Lisocabtagene maraleucelis a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. It is made from a patient’s own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment. Breyanzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant due to comorbidities or age, or relapsed or refractory disease after two or more lines of systemic therapy. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

Glofitamab: Hoffmann-La Roche

Glofitamab is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells. The drug candidate was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T-cells, a type of immune cell, and two regions that bind to CD20, a protein on B-cells, which can be healthy or malignant. This dual-targeting brings the T-cell in close proximity to the B-cell, activating the release of cancer cell-killing proteins from the T-cell. Columvi is part of Roche’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development programme that also includes Lunsumio® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and other blood cancers. The drug is currently in Phase III stage of development for treatment of B cell lymphoma.

NKTR-255: Nektar Therapeutics

NKTR-255 is an investigational drug developed by Nektar Therapeutics, designed as a polymer-conjugated interleukin-15 (IL-15) receptor agonist. Its primary goal is to enhance the immune system’s capacity to combat cancer by boosting the proliferation and survival of natural killer (NK) cells and memory CD8+ T cells. This mechanism involves engaging the entire IL-15 receptor complex, which may lead to the formation of long-term immunological memory and a sustained anti-tumor immune response. The drug is currently in Phase II/III stage of development for treatment of B cell lymphoma.

Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH

Zamtocabtagene autoleucel, also known as MB-CART2019.1, is an investigational chimeric antigen receptor T-cell (CAR-T) therapy developed by Miltenyi Biotec. This therapy targets both CD19 and CD20 antigens, making it a bispecific treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Zamtocabtagene autoleucel is designed to enhance the immune response against B-cell tumors by utilizing genetically modified T cells that express CARs targeting both CD19 and CD20. The therapy employs a lentiviral vector to transduce autologous T cells, which are then expanded and infused back into the patient after lymphodepleting chemotherapy. This dual targeting approach aims to overcome resistance mechanisms associated with single-target therapies, particularly in cases where the tumor may lose expression of one of the targets. The drug is currently in Phase II stage of development for treatment of B cell lymphoma.

MB-CART20.1: Miltenyi Biomedicine GmbH

MB-CART20.1 is an investigational CAR-T cell therapy engineered to target the CD20 protein, which is highly expressed on the surface of B-cells in certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. By modifying a patient’s T-cells to express chimeric antigen receptors (CARs) that recognize CD20, MB-CART20.1 enables the immune system to selectively attack and eliminate cancerous B-cells. This therapy is designed to offer a novel option for patients with relapsed or refractory CD20-positive malignancies, aiming to improve outcomes through enhanced tumor targeting and prolonged remission. Clinical trials are ongoing to assess its efficacy and safety. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

AVM0703: AVM Biotechnology

AVM0703 is a clinical-stage therapeutic that works by rapidly inducing the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT), which possess unique immune properties. Following a single dose of AVM0703, these supercharged immune cells appear in the bloodstream and target abnormal cells, including cancer cells, infected cells, and autoreactive lymphocytes. AVM0703’s mechanism is based on a proprietary suprapharmacologic dose of dexamethasone, designed to deliver high doses without typical side effects. This enhanced dexamethasone formulation triggers the activation and mobilization of AVM-NKT cells, offering a potent yet gentler treatment option by targeting malignancies and immune disorders with precision. The drug is currently in Phase I/II stage of development for treatment of B cell lymphoma.

LBS-007: Lin BioScience, Inc

LBS-007 is a novel targeted therapy for the treatment of a broad array of cancers. It has demonstrated activity against leukemia and solid tumors, especially in chemotherapy-resistant cell lines and other cancer cell lines. LBS-007 has obtained Orphan Drug Destination (ODD) for Acute Lymphoma Leukemia (ALL) from US FDA in 2018/March and entered a first-in-human Phase I/II trial. LBS-007 inhibits cancer cell replication by interrupting the S phase of the cell cycle. Its mechanism of action is to inhibit a key regulator protein of the cell cycle, CDC7. Inhibition of CDC7 stops the proliferation of tumor cells and results in cancer cell death. Because CDC7’s activity is often upregulated in cancer cells in comparison to healthy cells, it’s an ideal candidate for a targeted anti-cancer therapy. The drug is currently in Preclinical stage of development for treatment of B cell lymphoma.

The B-Cell Lymphoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma Treatment.
B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the B-Cell Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New B-Cell Lymphoma Drugs

B-Cell Lymphoma Companies

Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.

B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

B-Cell Lymphoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Unveil the future of B-Cell Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ B-Cell Lymphoma Market Drivers and Barriers

Scope of the B-Cell Lymphoma Pipeline Report

Coverage- Global
B-Cell Lymphoma Companies- Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc., Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED and others.
B-Cell Lymphoma Pipeline Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on B-Cell Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ B-Cell Lymphoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
B-Cell Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lisocabtagene maraleucel: Bristol Myers Squibb
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
MB-CART20.1: Miltenyi Biomedicine GmbH
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
LBS-007: Lin BioScience, Inc
Drug profiles in the detailed report…..
Inactive Products
B-Cell Lymphoma Key Companies
B-Cell Lymphoma Key Products
B-Cell Lymphoma- Unmet Needs
B-Cell Lymphoma- Market Drivers and Barriers
B-Cell Lymphoma- Future Perspectives and Conclusion
B-Cell Lymphoma Analyst Views
B-Cell Lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

The New Brain Hack: Why Silicon Valley Executives Are Switching to Nually’s Focus Fuel Gummies

Aurora, Colorado – March 24, 2024 – From the boardrooms of Silicon Valley to Wall Street’s high-stakes trading floors, high-achievers are embracing a new way to sharpen their mental edge. Instead of relying on coffee, energy drinks, or synthetic nootropics, they’re turning to Focus Fuel Gummies—Nually’s latest innovation in cognitive enhancement.

Designed to provide sustained focus without crashes or jitters, Focus Fuel Gummies are packed with nature’s most powerful brain-boosting ingredients, including Organic Ashwagandha, Yerba Mate, and Organic Lion’s Mane. This cutting-edge formula helps professionals stay sharp, reduce stress, and power through long hours of intense work—naturally.

“Executives, entrepreneurs, and creatives need sustained, crash-free focus to stay ahead in today’s hyper-competitive world,” says Andreea Popa, spokesperson for Nually. “With Focus Fuel, they can make high-stakes decisions, tackle complex problems, and work at peak performance—without relying on synthetic stimulants.”

The Future of Focus Is Here

From Silicon Valley coders working 16-hour days to high-pressure investment meetings, professionals in demanding industries are making the switch to Focus Fuel Gummies. Unlike traditional focus supplements that can lead to energy crashes, dependency, or unwanted side effects, Nually’s formula is designed to deliver clean, sustained mental energy without the downsides.

Why High-Performers Choose Focus Fuel Gummies

Natural, science-backed ingredients – No synthetic stimulants
Crash-free focus & mental clarity – Stay sharp for hours
Delicious, convenient, and effective – No pills, no powders, just results

Nually makes focus effortless—and enjoyable. Whether leading a boardroom meeting, developing the next big innovation, or pushing personal limits, Focus Fuel Gummies provide the brain boost needed to stay ahead.

Fuel The Mind, Unlock One’s Potential

With a delicious fruity flavor, no artificial stimulants, and scientifically-backed ingredients, Focus Fuel is the brain hack high-achievers have been waiting for.

Say goodbye to energy crashes and hello to sustained focus, mental clarity, and stress-free productivity. Focus Fuel Gummies are the go-to solution for tackling demanding projects, powering through long workdays, and staying sharp in any high-pressure environment.

Shop now, explore the full range of wellness gummies, or learn more at https://nually.com. The mind deserves the best—fuel it the Nually way!

About Nually

Nually is a wellness brand dedicated to making health simple, enjoyable, and effective. With a focus on science-backed, natural ingredients, Nually creates delicious, easy-to-take gummies that support focus, energy, relaxation, and overall well-being. Founded on the belief that wellness should feel like a treat, not a chore, Nually replaces bitter pills and messy powders with convenient, great-tasting solutions. Every product is carefully crafted to deliver real results without synthetic stimulants or unnecessary fillers. The brand supports mental clarity, boosts energy, and promotes relaxation, helping users feel and perform at their best.

Disclaimer: The statements made regarding this product have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your doctor before using any product. The news site hosting this press release is not associated with Nually. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

Media Contact
Company Name: Nually
Contact Person: Andreea Popa
Email: Send Email
Country: United States
Website: https://www.nually.com/

Flexible Packaging Market Size & Growth Opportunities – Revenue to Hit $238.91 Billion by 2029 – Arizton

“Flexible Packaging Market Research Report by Arizton”

According to Arizton’s latest research report, the global flexible packaging market is growing at a CAGR of 2.12% during 2023-2029.

Looking for More Information? Click:

https://www.focusreports.store/report/flexible-packaging-market

Report Scope:   

Market Size (2029): $238.91 Billion   

Market Size (2023): $210.62 Billion   

CAGR (2023-2029): 2.12%   

Historic Year: 2020-2022   

Base Year: 2023   

Forecast Year: 2024-2029   

Market Segmentation: Material, Application, Consumer Flexible Packaging, Product, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa   

The flexible packaging market is largely dominated by small and medium-sized enterprises (SMEs), while larger players adopt inorganic growth strategies, including mergers and acquisitions (M&As), to expand their operations globally. Larger companies benefit from technological capabilities and high-volume product lines, which help manage cost fluctuations. Meanwhile, smaller companies focus on customization, competing primarily on features and price. The niche segment with lower volumes relies heavily on smaller packaging providers. In the Asia-Pacific (APAC) region, the growth of e-commerce has significantly increased demand for protective packaging, with many new SMEs emerging to meet this need.

China’s well-established plastics industry, combined with low labor costs and easy access to raw materials, has helped packaging companies thrive in the competitive market. However, the industry faces challenges related to recycling and green packaging. By 2025, vendors are expected to transition to sustainable packaging materials, requiring significant investments in new machinery, which may impact SMEs. The market is also witnessing growing investments in bio-based plastics, which are expected to drive further innovation and market growth.

Key competitive factors include price, quality, regulatory compliance, distribution networks, and R&D investment. Leading players such as Amcor plc, Sealed Air Corporation, and Berry Global Inc. maintain strong market positions, focusing on sustainability and technological advancements to stay competitive.

Transforming the Flexible Packaging Market: The Role of AI and Robotics

The rapid advancement of industrial robotics and artificial intelligence (AI) is revolutionizing the packaging industry, particularly in areas like automated material selection, real-time damage detection, and enhanced recycling capabilities. These technologies are reshaping operational efficiency, safety, and sustainability in 2023, offering unprecedented precision, consistency, and adaptability. As robots become more sophisticated and integrated into packaging lines, they are essential for meeting the growing demands of modern supply chains.

However, the successful implementation of AI and robotics in packaging is not without challenges. Companies need to invest in smart machinery, employee training, and seamless system integration to fully leverage the benefits. Despite these hurdles, the potential for increased productivity, cost savings, and reduced environmental impact is significant.

AI-driven robots are particularly valuable in minimizing waste and reducing product damage through real-time damage detection and automated material selection. Additionally, AI-based sorting technologies enhance recycling efficiency and economic viability. Robotics also streamline the flexible packaging process by automating tasks such as cutting, sealing, and labeling, reducing human error, improving accuracy, and decreasing waste.

As the demand for sustainable packaging rises, AI and robotics will become integral to flexible packaging, helping companies meet both operational and environmental goals. Leading packaging companies like Tetra Pak, Amcor, Sealed Air, and Berry Global are already embracing these technologies to improve production efficiency, sustainability, and supply chain optimization.

Growth and Challenges in Europe Flexible Packaging Market

The flexible packaging market in Europe is projected to grow at a compound annual growth rate (CAGR) of 4.53% during the forecast period, driven by robust economic growth and increased disposable incomes. Vendors with advanced technological capabilities, such as those offering aseptic, retort, anti-counterfeit, and child-resistant packaging, are gaining a competitive edge. Key growth sectors include coffee, pet food, and fresh foods, with rising demand for single-serve packaging driven by smaller households and a preference for product variety.

In Western Europe, mature markets with higher disposable incomes, like Germany, France, Belgium, and the Netherlands, have a high demand for flexible packaging. Eastern Europe is expected to experience growth, fueled by rising real income and purchasing power. However, the ongoing challenges of Brexit may affect trade in high-volume countries like Germany and France. The packaging industry saw its highest consumption of plastics in 2020, and competition remains fierce due to the fragmented nature of the market. Differentiation and cost efficiency will continue to be key competitive factors in the European flexible packaging sector.

Key Market Development in the Global Flexible Packaging Market:

Companies are investing in a restructuring program to improve productivity and reduce overhead costs.
Berry Global is expanding its manufacturing capabilities, exemplified by the 2023 expansion of its film facility in Lewisburg, Tennessee.
In 2024, Amcor collaborated with Stonyfield Organic and Cheer Pack North America to launch the first all-PE spouted pouch.

Looking for More Information? Click: 

https://www.focusreports.store/report/flexible-packaging-market

Key Company Profiles

Amcor plc
Berry Global Inc.
Mondi
Sealed Air
TC Transcontinental
Sonoco
Huhtamaki
Constantia Flexibles
Ahlstrom
Greif
Smurfit WestRock
Aptar
All4Labels
Aluberg
American Packaging Corporation
Aran Group
Bioplast
Bischof+Klein
Bühler
Carcano
CCL Industries
Cellografica Gerosa
CLONDALKIN GROUP
Cosmo First
Coveris
Danaflex
DazPak
DI MAURO
Eco Flexibles
ePac Holdings
Etapak
EUROFOIL
Flexpack
Gascogne Flexible
Glenroy
Global-Pak
Goglio
Grupo Lantero
Guala Pack S.p.a.
Innovia Films
International Paper
ITP
KLEINER FLEXIBLE PACKAGING
Korozo Group
Krajcar Pack
LEEB FLEXIBLES
Notpla
Novolex
Perlen Packaging
Plastic Suppliers
Plastixx FFS Technologies
Polypak Packaging
Printpack

Market Segmentation

Material

Flexible Plastic
PE (Polyethylene)
BOPP (Biaxially Oriented Polypropylene)
CPP (Cast Polypropylene)
BOPET (Biaxially-oriented Polyethylene Terephthalate)
PA (Polyamide)
PET (Polyethylene Terephthalate)
PVC (Polyvinyl Chloride)
EVOH (Ethylene-Vinyl Alcohol)
Others
Flexible Paper
Foil

Application

Consumer Packaging
Industrial Packaging

Consumer Flexible Packaging

Bakery & Confectionery
Meat, Poultry & Seafood
Dairy
RTE
Frozen Food
Healthcare
Personal Care
Tea & Coffee
Pet Food
Others

Product

Bags & Sacks
Pouches
Others

Geography 

APAC

China
India
Australia
Japan
South Korea
New Zealand
The Rest of APAC

Europe

Germany
France
The UK
Italy
Benelux
Spain
Austria
Scandinavia
Switzerland
The Rest of Europe

North America

The US
Canada

Latin America

Mexico
Brazil
Argentina
Chile
Rest of Latin America

Middle East & Africa

Turkey
Egypt
Saudi Arabia
South Africa
The UAE
The Rest of the Middle East & Africa

What Key Findings Our Research Analysis Reveals?   

How big is the global flexible packaging market?

What is the growth rate of the global flexible packaging market?

Which region dominates the global flexible packaging market share?

What are the significant trends in the flexible packaging market?

Who are the key players in the global flexible packaging market?

Other Related Reports that Might be of Your Business Requirement

APAC Pharmaceutical Packaging Market – Focused Insights 2023-2028

https://www.focusreports.store/report/apac-pharmaceutical-packaging-market-insights-forecast

Europe Packaging Adhesives & Sealants Market – Focused Insights 2023-2028

https://www.focusreports.store/report/europe-packaging-adhesives-and-sealants-market-focused-insights

Why Arizton?

100% Customer Satisfaction

24×7 availability – we are always there when you need us

200+ Fortune 500 Companies trust Arizton’s report

80% of our reports are exclusive and first in the industry

100% more data and analysis

1500+ reports published till date

Post-Purchase Benefit   

1hr of free analyst discussion   
10% off on customization

About Us:   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.focusreports.store/report/flexible-packaging-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Flexible Packaging Market Size & Growth Opportunities – Revenue to Hit $238.91 Billion by 2029 – Arizton

Peritoneal Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Peritoneal Cancer pipeline constitutes 55+ key companies continuously working towards developing 60+ Peritoneal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Peritoneal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Peritoneal Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peritoneal Cancer Market.

Some of the key takeaways from the Peritoneal Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Peritoneal Cancer treatment therapies with a considerable amount of success over the years.
Peritoneal Cancer companies working in the treatment market are AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others, are developing therapies for the Peritoneal Cancer treatment

Emerging Peritoneal Cancer therapies in the different phases of clinical trials are – Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others are expected to have a significant impact on the Peritoneal Cancer market in the coming years.
In February 2025, Alphamab Oncology has administered the first dose in its randomized Phase III JSKN003-306 trial, evaluating JSKN003, an anti-HER2 biparatopic antibody-drug conjugate (ADC), for the treatment of ovarian cancer.
In December 2024, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that its Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) with chemotherapy, followed by maintenance with LYNPARZA® (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer, has met its primary endpoint of progression-free survival (PFS). The final analysis, conducted by an independent Data Monitoring Committee, showed that the KEYTRUDA plus LYNPARZA regimen significantly improved PFS compared to chemotherapy alone, demonstrating statistical and clinical significance.
In October 2024, Oncoinvent administered the first dose in its Phase II clinical trial of Radspherin, an alpha-radiation therapy targeting peritoneal carcinomatosis resulting from ovarian cancer. This randomized, controlled trial aims to evaluate the efficacy and safety of the treatment. The study’s primary objective is to compare progression-free survival between patients receiving Radspherin after surgery and those undergoing only pre-operative chemotherapy and surgery.

Peritoneal Cancer Overview

Peritoneal cancer is a rare type of cancer that occurs in the peritoneum, a thin layer of tissue that lines the abdomen and covers most of its organs. It is closely related to ovarian cancer and can cause similar symptoms. Peritoneal cancer can be primary, originating in the peritoneum itself, or secondary, spreading from other organs such as the ovaries, stomach, or colon. Symptoms may include abdominal pain or swelling, digestive issues, and unexplained weight loss. Treatment typically involves surgery, chemotherapy, and targeted therapies, depending on the cancer’s origin and stage.

Get a Free Sample PDF Report to know more about Peritoneal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight

Emerging Peritoneal Cancer Drugs Under Different Phases of Clinical Development Include:

Masitinib: AB Science
Azenosertib: Zentalis Pharmaceuticals
IMGN151: ImmunoGen
Bevacizumab: Hoffmann-La Roche
Nab-paclitaxel: Corcept Therapeutics
131 I-omburtamab: Memorial Sloan Kettering Cancer Center
Catumaxomab: LintonPharm Co.,Ltd.
Fulvestrant: M.D. Anderson Cancer Center
Bevacizumab: ImmunoGen, Inc.
Carboplatin: Merck Sharp & Dohme LLC
MORAb-202: Bristol-Myers Squibb
KAND567: Kancera AB
ZEN003694: Haider Mahdi
RC88: RemeGen Co., Ltd.
HS-20089: Hansoh BioMedical
navicixizumab: OncXerna Theraputics, Inc

Peritoneal Cancer Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Peritoneal Cancer Molecule Type

Peritoneal Cancer Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Peritoneal Cancer Pipeline Therapeutics Assessment

Peritoneal Cancer Assessment by Product Type
Peritoneal Cancer By Stage and Product Type
Peritoneal Cancer Assessment by Route of Administration
Peritoneal Cancer By Stage and Route of Administration
Peritoneal Cancer Assessment by Molecule Type
Peritoneal Cancer by Stage and Molecule Type

DelveInsight’s Peritoneal Cancer Report covers around 60+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Peritoneal Cancer product details are provided in the report. Download the Peritoneal Cancer pipeline report to learn more about the emerging Peritoneal Cancer therapies

Some of the key companies in the Peritoneal Cancer Therapeutics Market include:

Key companies developing therapies for Peritoneal Cancer are – Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck & Co, AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Astex Pharmaceuticals, APIM Therapeutics, Celsion, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, Alkermes, Zenith Epigenetics, Sutro Biopharma, K-Group Beta, Bio-Path Holdings, Celldex Therapeutics, Rhizen Pharmaceuticals, Shattuck Labs, Inc., SELLAS Life Sciences Group, LIPAC oncology, Oncoinvent AS, Mereo Biopharma, Solasia Pharma, Mersana Therapeutics, Zentalis Pharmaceuticals, Lumicell Inc., Avenge Bio, and others.

Peritoneal Cancer Pipeline Analysis:

The Peritoneal Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
Peritoneal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market.

Download Sample PDF Report to know more about Peritoneal Cancer drugs and therapies

Peritoneal Cancer Pipeline Market Drivers

Advancements in treatment, increasing Incidence, government Initiatives, collaborative Efforts, patient Advocacy Groups, are some of the important factors that are fueling the Peritoneal Cancer Market.

Peritoneal Cancer Pipeline Market Barriers

However, clinical Trial Challenges, high Development Costs, regulatory Hurdles, limited treatment Options and other factors are creating obstacles in the Peritoneal Cancer Market growth.

Scope of Peritoneal Cancer Pipeline Drug Insight

Coverage: Global
Key Peritoneal Cancer Companies: AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others
Key Peritoneal Cancer Therapies: Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others
Peritoneal Cancer Therapeutic Assessment: Peritoneal Cancer current marketed and Peritoneal Cancer emerging therapies
Peritoneal Cancer Market Dynamics: Peritoneal Cancer market drivers and Peritoneal Cancer market barriers

Request for Sample PDF Report for Peritoneal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Peritoneal Cancer Report Introduction

2. Peritoneal Cancer Executive Summary

3. Peritoneal Cancer Overview

4. Peritoneal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Peritoneal Cancer Pipeline Therapeutics

6. Peritoneal Cancer Late Stage Products (Phase II/III)

7. Peritoneal Cancer Mid Stage Products (Phase II)

8. Peritoneal Cancer Early Stage Products (Phase I)

9. Peritoneal Cancer Preclinical Stage Products

10. Peritoneal Cancer Therapeutics Assessment

11. Peritoneal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peritoneal Cancer Key Companies

14. Peritoneal Cancer Key Products

15. Peritoneal Cancer Unmet Needs

16 . Peritoneal Cancer Market Drivers and Barriers

17. Peritoneal Cancer Future Perspectives and Conclusion

18. Peritoneal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peritoneal Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck

Solar Pool Supply Expands Product Line with Innovative GeoBubble™ Pool Covers

Lakeside, CA – March 24, 2025 – Solar Pool Supply, a leading retailer of pool products and heating solutions, is pleased to announce the addition of GeoBubble™ pool covers to its growing product portfolio. As part of its commitment to offering cutting-edge pool technology, Solar Pool Supply now carries multiple variations of the innovative GeoBubble™ covers, designed to enhance pool efficiency, reduce maintenance costs, and improve sustainability for pool owners.

GeoBubble EnergyGuard - Best seller

The GeoBubble™ technology, designed in the UK by Plastipack, introduces a breakthrough in pool cover durability and performance. The product’s innovative bubble design minimizes stress points that can lead to premature wear, thereby extending the cover’s lifespan. While traditional pool covers generally last 1-2 years, GeoBubble will last around 7-8 years. In addition, the technology is optimized for heat retention, reducing pool evaporation by up to 98% and inhibiting algae growth. This helps pool owners conserve energy and maintain comfortable water temperatures.

“At Solar Pool Supply, we are always looking for innovative solutions that help our customers enhance their pool experience while reducing costs and environmental impact,” said Kevin Kearns, Solar Pool Supply CMO. “GeoBubble™ covers align perfectly with our mission of providing high-quality, sustainable products. These covers not only improve energy efficiency but also simplify maintenance and water conservation, making them an excellent investment for any pool owner.”

Solar Pool Supply carries a comprehensive range of GeoBubble™ covers, including GeoBubble EnergyGuard™, GeoBubble Sol+Guard™, GeoBubble RaeGuard™, and GeoBubble CoolGuard™. Each product is tailored for specific pool requirements – retain heat, block sunlight, or improve energy savings – maintaining optimal performance in different environmental conditions. They come in various colors and designs.

As pool owners look for effective solutions to enhance pool maintenance and efficiency, Solar Pool Supply remains committed to sourcing products that prioritize performance and quality.

For more information on GeoBubble™ pool covers and to explore Solar Pool Supply’s full range of solar heating solutions, please visit https://solarpoolsupply.com.

About Solar Pool Supply

Solar Pool Supply is one of the largest retailers of solar pool heaters in the US, carrying top brands known for quality and efficiency. Committed to sustainable pool heating solutions, Solar Pool Supply provides nationwide shipping, making sustainable pool heating accessible to customers across the country.

Socials: Facebook, Instagram

Media Contact
Company Name: Solar Pool Supply
Contact Person: Kevin Kearns
Email: Send Email
Phone: (619) 748-1141
Country: United States
Website: https://solarpoolsupply.com/

EKOUAER Wins Multiple Prestigious International Media Awards, Showcasing Brand Excellence

Newyork-International lifestyle brand EKOUAER has garnered a series of heavyweight accolades and recommendations from global authoritative media outlets in 2024, thanks to its innovative designs and exceptional quality. These honors not only solidify its leadership in the fashion and lifestyle sectors but also highlight widespread recognition from consumers and industry experts alike.

Featured in Shop TODAY 2024 “AS SEEN ON” Annual List

Multiple EKOUAER products were selected for Shop TODAY 2024’s “AS SEEN ON” Annual Picks, a highly influential list curated by NBC’s TODAY show, spotlighting Amazon’s best-selling and top-rated items of the year. EKOUAER’s standout offerings, celebrated for their unique designs, premium comfort, and affordability, have become hot favorites for holiday gifting.

CNN Underscored “Editor’s Pick 2024”

EKOUAER’s Winter Loungewear Collection earned a coveted spot in CNN Underscored’s “Editor’s Favorite Winter Pajamas”* list. The editorial team praised its “ultra-soft, skin-friendly fabrics, chic minimalist tailoring, and thoughtful details that balance practicality with aesthetics,” dubbing it “the ultimate cozy companion for chilly seasons.”

Forbes “Best Beach Cover-Ups” Recognition

EKOUAER’s Beach Cover-Up Series was named one of the “Best Beach Cover-Ups” in Forbes’ annual roundup, hailed as a must-have for style-savvy travelers. Editors applauded its “lightweight, breathable fabric, versatile elegance, and seamless fusion of sun protection with runway-ready flair,” noting that it “redefines standards for resortwear.”

About EKOUAER

Founded in 2015, EKOUAER is a global fashion brand committed to delivering high-quality, comfort-focused sleepwear and loungewear. Leveraging proprietary fabric technologies for unparalleled softness, the brand has rapidly expanded its reach, serving millions of customers across 180+ countries. EKOUAER remains dedicated to enhancing everyday comfort, prioritizing designs that blend luxury, functionality, and timeless style to elevate the sleep and leisure experience.

Media Contact
Company Name: EKOUAER
Contact Person: Dana LI
Email: Send Email
Country: United States
Website: https://ekouaer.com